Genomic landscape of KRAS G12C mutations across diverse tumor types
A large-scale RWD analysis of KRAS G12C prevalence and associated biomarkers
Evaluation of Immune Biomarkers by KRASG12C, KRAS non-G12C, and KRAS Wildtype Status
Comparison of TMB-high (defined as >10 mut/Mb), PD-L1-positive, and MSI-High cases between KRAS G12C and KRAS non-G12C and between KRAS G12C and KRAS wildtype cohorts. TMB, tumor mutational burden; MSI, microsatellite instability. *FDR-P <0.05 and was considered statistically significant; **FDR-P<0.001; ***FDR-P<0.0001.
Lens Library
